Erbil K M, Sen S E, Zincke H, Jones J D
Cancer. 1986 Apr 1;57(7):1389-94. doi: 10.1002/1097-0142(19860401)57:7<1389::aid-cncr2820570725>3.0.co;2-g.
A prospective study was done to evaluate the roles of serum N-acetylneuraminic acid (NANA) and the lipid-bound subfraction of sialic acid (LSA) concentrations in the detection and staging of cancer, and the follow-up of treatment in patients with genitourinary malignancies. Multiple determinations were obtained in 177 subjects: 90 normal volunteers, 38 patients with prostate cancer, 20 patients with bladder cancer, 15 patients with renal cell cancer, and 14 patients with benign urologic diseases. The results showed a low incidence of elevated values in patients with early stages of cancer and a high incidence of false-positive values with serum NANA concentrations in patients with benign urologic diseases, especially prostatitis. Serum NANA and LSA concentrations were highly correlated with the stage and grade in patients with advanced urologic cancer, and may be used as markers of tumor activity during follow-up under treatment; currently, however, they are not useful in the screening of patients for urologic cancer. Their usefulness in prostatic cancer is at least comparable to that of acid phosphatase determinations by the enzymatic and radioimmunoassay methods, which were elevated in a smaller percentage of patients with prostate cancer than were the NANA or LSA concentrations.
开展了一项前瞻性研究,以评估血清N-乙酰神经氨酸(NANA)和唾液酸脂质结合亚组分(LSA)浓度在泌尿生殖系统恶性肿瘤患者癌症检测、分期及治疗随访中的作用。对177名受试者进行了多次测定,其中包括90名正常志愿者、38名前列腺癌患者、20名膀胱癌患者、15名肾细胞癌患者和14名良性泌尿系统疾病患者。结果显示,癌症早期患者中NANA值升高的发生率较低,而良性泌尿系统疾病患者,尤其是前列腺炎患者,血清NANA浓度出现假阳性值的发生率较高。血清NANA和LSA浓度与晚期泌尿系统癌症患者的分期和分级高度相关,可作为治疗随访期间肿瘤活性的标志物;然而目前,它们在泌尿生殖系统癌症患者筛查中并无用处。它们在前列腺癌中的作用至少与酶法和放射免疫分析法测定酸性磷酸酶相当,前列腺癌患者中酸性磷酸酶升高的比例低于NANA或LSA浓度升高的比例。